The history of maternal immunization

Kachikis, Alisa; Eckert, Linda O.; Englund, Janet A.

doi:10.1016/b978-0-12-814582-1.00001-2

Cited by 9 publications

(17 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The finding clearly suggests many of the mothers who were the main target of population as far this study is concerned, many of them manly comprised of the youths. This study agrees with one carried by Kachikis et al, (2020), that found maternal age is a factor influencing adoption of routine immunisation. On the question of marital status, it was established that majority of the respondent are married and this was supported by 61.4%.…”

Section: Response Ratesupporting

confidence: 93%

Influence of Message Content in Persuasive Communication on Adoption of Routine Immunisation of Children Aged 0-5 years in Bomet County, Kenya

Amatu¹,

Mberia²,

Ngula³

2021

J. Dev and Commun Stud

View full text Add to dashboard Cite

An estimated two to three million annual deaths from vaccine preventable diseases (VPDs) are prevented through immunisation. Currently about 19.5 million infants miss out on routine immunisation globally. We carried out a study on the role of message content in persuasive communication on adoption of routine immunisation services. The study employed a mixed method research design. A sample of 384 caregivers was used. Data was collected using interviewer administered questionnaires and Key Informant Interviews. The key informants interviewed were taken with sub-county medical officer of health, health promotion officer and EPI coordinator. Both descriptive and inferential statistics were applied in the analysis. The study findings were that message content had positive influence on adoption of routine immunisation. The study recommended that routine immunisation messages be made frequently available, targeted and tailored to the caregivers. Secondly, the community should be involved in advocacy towards adoption of routine immunisation, to create ownership and adoption sustainability. Additionally, health workers should be motivated towards good practice in health worker-client communication, specifically, persuasive communication to build trust from the caregivers. The researcher recommends comparative studies should be conducted, comparing the well performing counties with Bomet County, Kenya.An estimated two to three million annual deaths from vaccine preventable diseases (VPDs) are prevented through immunisation. Currently about 19.5 million infants miss out on routine immunisation globally. We carried out a study on the role of message content in persuasive communication on adoption of routine immunisation services. The study employed a mixed method research design. A sample of 384 caregivers was used. Data was collected using interviewer administered questionnaires and Key Informant Interviews. The key informants interviewed were taken with sub-county medical officer of health, health promotion officer and EPI coordinator. Both descriptive and inferential statistics were applied in the analysis. The study findings were that message content had positive influence on adoption of routine immunisation. The study recommended that routine immunisation messages be made frequently available, targeted and tailored to the caregivers. Secondly, the community should be involved in advocacy towards adoption of routine immunisation, to create ownership and adoption sustainability. Additionally, health workers should be motivated towards good practice in health worker-client communication, specifically, persuasive communication to build trust from the caregivers. The researcher recommends comparative studies should be conducted, comparing the well performing counties with Bomet County, Kenya.

show abstract

Section: Response Ratesupporting

confidence: 93%

Influence of Message Content in Persuasive Communication on Adoption of Routine Immunisation of Children Aged 0-5 years in Bomet County, Kenya

Amatu¹,

Mberia²,

Ngula³

2021

J. Dev and Commun Stud

View full text Add to dashboard Cite

show abstract

“…Inclusion of pregnant individuals in immunization research is complex because of many factors, including the intricacies of the maternal and neonatal immune systems and transplacental antibody transfer to the fetus. 38 Clinical research studies for pregnant individuals must also consider factors such as disease burden and epidemiology, risks to the infant, maternal vaccination acceptance, and potential adverse effects in both the mother and infant. Although some progress has been made in health policies to support the inclusion of pregnant individuals and children in clinical vaccination trials, most notably during the coronavirus disease (COVID-19) pandemic, it remains a challenging area of public health.…”

Section: Research Gaps and Unanswered Questionsmentioning

confidence: 99%

Understanding New Recommendations for Respiratory Syncytial Virus Prevention in Pregnancy

Horgan,

Hughes,

Waller

et al. 2024

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is a significant cause of infant morbidity and mortality worldwide with peak hospitalization rates for RSV-mediated illnesses between 2 and 3 months of life. Until very recently, prevention strategies for RSV involved primarily passive immunization of neonates at high risk with monoclonal antibodies and promotion of breastfeeding. The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices now recommends passive immunization of all neonates with monoclonal antibodies during RSV season, and the American Association of Pediatrics has endorsed this practice. The U.S. Food and Drug Administration (FDA) recently approved a vaccination for RSV in pregnancy. The CDC's Advisory Committee on Immunization Practices has recently recommended RSV vaccination for all pregnant patients between 32 and 36 weeks of gestation who are anticipated to deliver during RSV season if they are not planning nirsevimab for their infants. This recommendation has been endorsed by the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine. In this clinical perspective, we review the scientific evidence, potential concerns, challenges, and future considerations for RSV vaccination in pregnancy.

show abstract

“…Interventional research in pregnancy has remained contentious since the formalisation of human research ethics in the mid-20th century 1 2. Although neither the Nuremberg Code (1947) nor the World Medical Association’s Declaration of Helsinki (1964) explicitly referred to pregnant women, their participation in interventional research was restricted following a number of highly publicised cases of harm caused by medical interventions in pregnancy 1.…”

Section: Introductionmentioning

confidence: 99%

“…Although neither the Nuremberg Code (1947) nor the World Medical Association’s Declaration of Helsinki (1964) explicitly referred to pregnant women, their participation in interventional research was restricted following a number of highly publicised cases of harm caused by medical interventions in pregnancy 1. For instance, the use of thalidomide in pregnancy resulted in many thousands of congenital anomalies and infant deaths in the 1960s, while antenatal use of diethylstilbestrol was recognised as a cause of cancer in women and their female offspring in the 1970s 1–3. Due to perceptions of greater susceptibility to harm, pregnant women were increasingly excluded from interventional research and even reclassified as a ‘vulnerable population’ by the US Department of Health and Human Services in 1975 1 2…”

Section: Introductionmentioning

confidence: 99%

Qualitative interview study exploring the perspectives of pregnant women on participating in controlled human infection research in the UK

Dorey,

Theodosiou,

Read

et al. 2023

BMJ Open

View full text Add to dashboard Cite

IntroductionPregnant women have been historically excluded from interventional research. While recent efforts have been made to improve their involvement, there remains a disparity in the evidence base for treatments available to pregnant women compared with the non-pregnant population. A significant barrier to the enrolment of pregnant women within research is risk perception and a poor understanding of decision-making in this population.ObjectiveAssess the risk perception and influences on decision-making in pregnant women, when considering whether to enrol in a hypothetical interventional research study.DesignSemistructured interviews were undertaken, and thematic analysis was undertaken of participant responses.ParticipantsTwelve pregnant women were enrolled from an antenatal outpatient clinic.ResultsParticipants were unanimously positive about enrolling in the proposed hypothetical interventional study. Risk perception was influenced by potential risks to their fetus and their previous experiences of healthcare and research. Participants found the uncertainty in quantifying risk for new research interventions challenging. They were motivated to enrol in research by altruism and found less invasive research interventions more tolerable.ConclusionIt is vital to understand how pregnant women balance the perceived risks and benefits of interventional research. This may help clinicians and scientists better communicate risk to pregnant women and address the ongoing under-representation of pregnant women in interventional research.

show abstract

The history of maternal immunization

Cited by 9 publications

References 51 publications

Influence of Message Content in Persuasive Communication on Adoption of Routine Immunisation of Children Aged 0-5 years in Bomet County, Kenya

Influence of Message Content in Persuasive Communication on Adoption of Routine Immunisation of Children Aged 0-5 years in Bomet County, Kenya

Understanding New Recommendations for Respiratory Syncytial Virus Prevention in Pregnancy

Qualitative interview study exploring the perspectives of pregnant women on participating in controlled human infection research in the UK

Contact Info

Product

Resources

About